Iodopovidone as a pleurodesis agent: setting standards for clinical pleural research

Our plain-English summary of Iodopovidone as a pleurodesis agent: setting standards for clinical pleural research, by A.H. Diacon (Respirology, 2010).

The study

• Author: A.H. Diacon
• Journal: Respirology
• Published: 2010;15(1):4-5
• Type of article: Editorial, Comment
• Cited by: 1 article, as counted by NIH iCite
• Read it: PubMed · Publisher

In plain English

This article was an editorial, not a research study, and it reported no new data. The author commented on two papers in the same issue of Respirology that evaluated iodopovidone for pleurodesis (a procedure to stop fluid re-collecting around the lung) in malignant pleural effusion. One was a retrospective study in patients by Andrade Neto and co-workers. The other was a prospective study in rabbits by Guo and co-workers comparing iodopovidone with doxycycline. As background, the author stated, citing earlier work, that symptomatic effusions occur in almost all patients with mesothelioma. The author called the rabbit study an exemplary preclinical study. The author described the patient study's main end point, no repeat pleural intervention on the same side, as clinically relevant. The author noted that talc has a tainted safety record. The author also noted that eye toxicity had been reported in three cases where iodopovidone was used at much higher doses. The author argued that human studies of pleurodesis agents should be prospective and called for multicentre collaborative pleural research networks using standard protocols.

We wrote this plain-English summary from the full article with the help of AI, and a second AI model checked each sentence against the article. It is not the authors' wording; the abstract and the article are their own account.

What the study did and found

• Design: Editorial (commentary on two other papers in the same journal issue); no original data
• Who was studied: No population was studied by the author. The editorial discussed a retrospective study of patients with malignant pleural effusion (Andrade Neto and co-workers) and a prospective rabbit study (Guo and co-workers).
• Exposure: Iodopovidone as a chemical pleurodesis agent, with talc discussed as the most commonly used agent; asbestos exposure was not discussed
• Main results:
  • Author's background statement, citing earlier work (not a finding of this article): symptomatic pleural effusion occurs in almost all patients with mesothelioma, in 50% of patients with breast cancer and in 25% of patients with lung cancer
  • Author's opinion: the rabbit study by Guo and co-workers was an exemplary preclinical study showing that pleurodesis could be achieved without prohibitive toxicity
  • Author's description of the Andrade Neto study: success was defined as no need for a repeat pleural intervention on the same side after chest tube pleurodesis; the author regarded this end point as clinically relevant
  • Author's statement on safety: talc has a tainted safety record
  • Author's statement on safety: eye (ocular) toxicity was reported in three cases where iodopovidone was used, at much higher doses than in the Andrade Neto study
• The authors' conclusion: The author argued that studies of pleurodesis agents in humans should be prospective. The author called for multicentre collaborative pleural research networks working to standard protocols.

Topics

The National Library of Medicine indexes this study under subjects our site covers: Talc and vermiculite.

Medical terms in this study, explained in our Lexicon: Pleurodesis.

Related studies

• A randomized controlled trial of the efficacy of cosmetic talc compared with iodopovidone for chemical pleurodesis — R. Agarwal, A.S. Paul, et al. (2011)
• Tumor type influences the effectiveness of pleurodesis in malignant effusions — S. Bielsa, P. Hernández, et al. (2011)
• Success rate of medical thoracoscopy and talc pleurodesis in malignant pleurisy: A single-centre experience — J. Leemans, C. Dooms, et al. (2018)
• Predictors of clinical use of pleurodesis and/or indwelling pleural catheter therapy for malignant pleural effusion — E.T.H. Fysh, S. Bielsa, et al. (2015)
• Mechanisms of pleurodesis — F. Rodriguez-Panadero, A. Montes-Worboys (2012)
• Survival in patients with malignant pleural effusion undergoing talc pleurodesis — M. Hassan, R.M. Mercer, et al. (2019)

Browse more research in Respirology, or return to medical research.